Andere Sprachen Prelude Therapeutics Incorporated

Aktien

A2QDGN

US74065P1012

PRLD

Verzögert Nasdaq Andere Börsenplätze 19:00:00 03.07.2024			% 5 Tage	% 1. Jan.
3.62 ^USD	-2.95%		-2.16%	-15.22%

20.06.	PRELUDE THERAPEUTICS INCORPORATED : Barclays gibt eine Verkaufsbewertung ab	ZM
12.06.	Transcript : Prelude Therapeutics Incorporated Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 10:40 AM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences	03.06.
Prelude Therapeutics Files for $400 Million Mixed Shelf	31.05.
Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference	09.05.
Prelude Therapeutics Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2024	07.05.
Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update	07.05.
Bryant D. Lim to Serve as Principal Financial Officer and Principal Accounting Officer of Prelude Therapeutics Incorporated	10.04.
Prelude Therapeutics Incorporated Announces Chief Financial Officer Changes	10.04.
Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting	09.04.
Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting	05.03.
Prelude Therapeutics to Participate in Barclays Global Healthcare Conference	29.02.
Prelude Therapeutics Shares Surge Following Shelf Registration	16.02.
Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024	15.02.
Prelude Therapeutics Incorporated Reports Earnings Results for the Full Year Ended December 31, 2023	15.02.
Prelude Therapeutics Incorporated(NasdaqGS:PRLD) dropped from NASDAQ Biotechnology Index	15.12.
Prelude Therapeutics Incorporated announced that it has received $24.999997 million in funding	13.12.
Prelude Therapeutics Announces $25 Million Private Placement	11.12.
Prelude Therapeutics Incorporated : Announces $25 Million Private Placement - Form 8-K	11.12.
Prelude Therapeutics Incorporated announced that it expects to receive $24.999997 million in funding	11.12.
Prelude Therapeutics Incorporated Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	01.11.
Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results	01.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Prelude Therapeutics Incorporated

Aktien

A2QDGN

US74065P1012

PRLD

Andere Sprachen

Filter